AZD7442 Pharmacokinetics, Pharmacodynamics, and safety evaluation in pediatrics

Trial Identifier: D8850C00006
Sponsor: AstraZeneca
NCTID:: NCT05281601
Start Date: March 2022
Primary Completion Date: July 2024
Study Completion Date: July 2024

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
BE Bruxelles, BE, 1200
BE Leuven, BE, 3000
BR Belo Horizonte, BR, 30130-100
BR Botucatu, BR, 18610-070
BR Porto Alegre, BR, 90035-001
DE Frankfurt am Main, DE, 60590
DE Köln, DE, 50924
ES Esplugues de Llobregat (Barc), ES, 08950
ES Madrid, ES, 28041
GB Edinburgh, GB, EH9 1LF
GB Leeds, GB, LS1 3EX
GB London, GB, SW17 0RE
GB London, GB, W2 1NY
GB Manchester, GB, M13 9WL
GB Newcastle-upon-Tyne, GB, NE1 4LP
GB Southampton, GB, SO16 6YD
MX Mérida, MX, 97070
MX Mexico, MX, 14000
UA Dnipro, UA, 49006
UA Dnipropetrovsk, UA, 49100
UA Krivoi Rog, UA, 49006
UA Zaporizhzhia, UA, 69076
US, CA Long Beach, CA, US, 90806
US, CA Los Angeles, CA, US, 90095
US, CA Stanford, CA, US, 94305
US, CO Aurora, CO, US, 80045
US, DC Washington, DC, US, 20007
US, FL Miami, FL, US, 33155
US, FL Saint Petersburg, FL, US, 33701
US, ID Idaho Falls, ID, US, 83404
US, MI Ann Arbor, MI, US, 48109
US, MO Kansas City, MO, US, 64108
US, NY Stony Brook, NY, US, 11794
US, RI Providence, RI, US, 02903
US, SC Mount Pleasant, SC, US, 29464